UPDATE: J.P. Morgan Lowers MAKO Surgical's PT

According to a research report published this morning, J.P. Morgan lowered MAKO Surgical's

PT from $33 to $28. In the report, J.P. Morgan said, "Following disappointing 1Q12 results, we conducted nine in-depth interviews with orthopedic surgeons who are either part of Mako's current user base or trained on Rio and evaluating purchase. While we were hoping, given the pullback in the shares, to come away with a clearer view than from prior checks, feedback was once again decidedly mixed and by no means universal even across a familiar physician base. It was similar feedback that led us to reiterate our Neutral rating back in December, and we remain on the sidelines today." J.P. Morgan maintains its Neutral rating on MAKO Surgical, which is currently trading at $21.86.